ESTA icon

Establishment Labs

40.11 USD
-0.70
1.72%
At close Apr 1, 4:00 PM EDT
After hours
40.11
+0.00
0.00%
1 day
-1.72%
5 days
-3.05%
1 month
-6.46%
3 months
-11.42%
6 months
-1.11%
Year to date
-11.42%
1 year
-17.81%
5 years
205.72%
10 years
62.06%
0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

137% more call options, than puts

Call options by funds: $66M | Put options by funds: $27.9M

104% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 25

14% more funds holding in top 10

Funds holding in top 10: 7 [Q3] → 8 (+1) [Q4]

12% more capital invested

Capital invested by funds: $1.08B [Q3] → $1.22B (+$133M) [Q4]

2.24% more ownership

Funds ownership: 89.66% [Q3] → 91.9% (+2.24%) [Q4]

8% less funds holding

Funds holding: 129 [Q3] → 119 (-10) [Q4]

30% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 30

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$52
30%
upside
Avg. target
$52
30%
upside
High target
$52
30%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Stephens & Co.
Mason Carrico
18% 1-year accuracy
5 / 28 met price target
30%upside
$52
Overweight
Reiterated
6 Mar 2025

Financial journalist opinion

Neutral
Business Wire
1 week ago
Establishment Labs Notes Presentation of 5-Year Results from Motiva U.S. IDE Study at The Aesthetic MEET 2025
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, noted the presentation today of an update on the Motiva US IDE Study. The update will include five-year patient follow-up data for primary augmentation subjects. The Medical Director of the Study, Dr. Caroline Glicksman, who is also an Investigator in the Study, will present the re.
Establishment Labs Notes Presentation of 5-Year Results from Motiva U.S. IDE Study at The Aesthetic MEET 2025
Neutral
PRNewsWire
3 weeks ago
Establishment Labs® Announces Meghan Trainor as Brand Partner Following Her Breast Augmentation with Motiva Implants®
The campaign is the first-of-its-kind partnership and follows the US FDA approval of Motiva Implants®  NEW YORK , March 6, 2025 /PRNewswire/ -- Establishment Labs® Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced a partnership with GRAMMY Award-winning hitmaker Meghan Trainor. Meghan recently received Motiva Implants® after careful consideration and research.
Establishment Labs® Announces Meghan Trainor as Brand Partner Following Her Breast Augmentation with Motiva Implants®
Neutral
Seeking Alpha
1 month ago
Establishment Labs Holdings Inc. (ESTA) Q4 2024 Earnings Call Transcript
Establishment Labs Holdings Inc. (NASDAQ:ESTA ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Raj Denhoy - CFO Juan Chacón-Quirós - CEO Peter Caldini - President Conference Call Participants Anthony Petrone - Mizuho Group Allen Gong - JPMorgan Josh Jennings - TD Cowen Marie Thibault - BTIG Joanne Wuensch - Citibank Matt Taylor - Jefferies Harrison Parsons - Stephens Inc Operator Good afternoon. Welcome to Establishment Labs Fourth Quarter 2024 Earnings Call.
Establishment Labs Holdings Inc. (ESTA) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Establishment Labs Holdings Inc. (ESTA) Reports Q4 Loss, Lags Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.79 per share a year ago.
Establishment Labs Holdings Inc. (ESTA) Reports Q4 Loss, Lags Revenue Estimates
Neutral
Business Wire
1 month ago
Establishment Labs Reports Fourth Quarter and Full Year 2024 Financial Results and Reaffirms 2025 Guidance
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2024 and reaffirmed 2025 guidance. Fourth Quarter Highlights and Outlook Fourth quarter revenue of $44.5 million, consistent with preannouncement on January 13. Motiva Implants approved and la.
Establishment Labs Reports Fourth Quarter and Full Year 2024 Financial Results and Reaffirms 2025 Guidance
Neutral
Business Wire
1 month ago
Establishment Labs to Present at TD Cowen's 45th Annual Health Care Conference
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in TD Cowen's 45th Annual Health Care Conference. Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, are scheduled to present in a fireside chat on Tuesday, March 4, 2025 at 2:30 p.m. ET. A live w.
Establishment Labs to Present at TD Cowen's 45th Annual Health Care Conference
Neutral
Business Wire
1 month ago
Establishment Labs to Present at Citi's 2025 Unplugged Medtech and Life Sciences Access Day
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in a fireside chat at Citi's 2025 Unplugged Medtech and Life Sciences Access Day. Juan José Chacón-Quirós, Chief Executive Officer and Founder; Peter Caldini, President; and Raj Denhoy, Chief Financial Officer, are scheduled to present on Thursday,.
Establishment Labs to Present at Citi's 2025 Unplugged Medtech and Life Sciences Access Day
Neutral
Business Wire
1 month ago
Establishment Labs Launches Preservé™
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness in breast aesthetics and reconstruction, announced it has launched Preservé™ in Brazil, the first country in its global rollout. Preservé is the second product in the Company's minimally invasive platform, building upon the technologies and techniques developed with Mia Femtech®, Establishment Labs' minimally invasive experience. “The.
Establishment Labs Launches Preservé™
Neutral
Business Wire
1 month ago
Establishment Labs to Announce Fourth Quarter 2024 Financial Results on February 26
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2024, after the market closes on Wednesday, February 26, 2025, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S.
Establishment Labs to Announce Fourth Quarter 2024 Financial Results on February 26
Neutral
Business Wire
2 months ago
Establishment Labs Announces CEO Transition
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness in breast aesthetics and reconstruction, announced today that after twenty years as Chief Executive Officer (CEO), Juan José Chacón-Quirós has decided to retire as CEO, effective March 1, 2025. Peter Caldini, currently President of Establishment Labs, will serve as Interim CEO after that date. Mr. Chacón-Quirós will continue with Esta.
Establishment Labs Announces CEO Transition
Charts implemented using Lightweight Charts™